M&A / Deals Incyte gobbles up Star’s Vega haematology unit in $2bn deal PharmaphorumIncyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.HematologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) Pharmaphorum Incyte has agreed to buy Star Therapeutics’ Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche doubles down on BTK with $2.3bn Nurix dealNext: ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
